What question did this study set out to answer?

This research aims to evaluate the incidence and outcomes of the no-reflow phenomenon following coronary intervention in acute myocardial infarction patients.

August 31, 2010Journal of Interventional Cardiology148 citations

View Full Paper

No‐Reflow Phenomenon Following Percutaneous Coronary Intervention for Acute Myocardial Infarction: Incidence, Outcome, and Effect of Pharmacologic Therapy

SRShereif H. Rezkalla KDKodlipet Dharmashankar IAIhab B. Abdalrahman

Key Points

This research aims to evaluate the incidence and outcomes of the no-reflow phenomenon following coronary intervention in acute myocardial infarction patients.
Examined the incidence of no-reflow during percutaneous coronary intervention for STEMI

Structured PICO

Does pharmacologic therapy (nicardipine, nitroprusside, verapamil) improve flow in STEMI patients with no-reflow phenomenon following PCI?

Population

STEMI patients with no-reflow phenomenon following percutaneous coronary intervention

Intervention

Pharmacologic therapy (nicardipine, nitroprusside, and verapamil)

Comparator

Untreated (for prognosis) or compared to each other (for efficacy)

Outcome

Flow improvementsurrogate

Nicardipine, nitroprusside, and verapamil are equally effective in treating no-reflow during STEMI PCI, a condition that otherwise carries a poor prognosis.

Abstract

NR is common in STEMI. Treatment with nicardipine, nitroprusside, and verapamil are equally effective in improving flow. If not treated, prognosis is poor.

Ask AI

Helpful

Bookmark

View Full Paper

Ask AI

Helpful

Bookmark

View Full Paper

No‐Reflow Phenomenon Following Percutaneous Coronary Intervention for Acute Myocardial Infarction: Incidence, Outcome, and Effect of Pharmacologic Therapy

Key Points

Structured PICO

Abstract

Cite This Study

Also Consider

Also Consider